241 related articles for article (PubMed ID: 24957778)
1. Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.
Chikere K; Webb NE; Chou T; Borm K; Sterjovski J; Gorry PR; Lee B
Retrovirology; 2014 Jun; 11():48. PubMed ID: 24957778
[TBL] [Abstract][Full Text] [Related]
2. Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System.
Webb NE; Lee B
Methods Mol Biol; 2016; 1354():3-20. PubMed ID: 26714701
[TBL] [Abstract][Full Text] [Related]
3. Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.
Chikere K; Chou T; Gorry PR; Lee B
Virology; 2013 Jan; 435(1):81-91. PubMed ID: 23217618
[TBL] [Abstract][Full Text] [Related]
4. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
[TBL] [Abstract][Full Text] [Related]
5. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
6. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.
Johnston SH; Lobritz MA; Nguyen S; Lassen K; Delair S; Posta F; Bryson YJ; Arts EJ; Chou T; Lee B
J Virol; 2009 Nov; 83(21):11016-26. PubMed ID: 19692480
[TBL] [Abstract][Full Text] [Related]
7. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.
Joseph SB; Arrildt KT; Swanstrom AE; Schnell G; Lee B; Hoxie JA; Swanstrom R
J Virol; 2014 Feb; 88(4):1858-69. PubMed ID: 24307580
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of subtype C envelope tropism for memory CD4
Gartner MJ; Gorry PR; Tumpach C; Zhou J; Dantanarayana A; Chang JJ; Angelovich TA; Ellenberg P; Laumaea AE; Nonyane M; Moore PL; Lewin SR; Churchill MJ; Flynn JK; Roche M
Retrovirology; 2020 Aug; 17(1):24. PubMed ID: 32762760
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic Correlates of HIV-1 Macrophage Tropism.
Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
[TBL] [Abstract][Full Text] [Related]
11. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
[TBL] [Abstract][Full Text] [Related]
12. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.
Wilen CB; Parrish NF; Pfaff JM; Decker JM; Henning EA; Haim H; Petersen JE; Wojcechowskyj JA; Sodroski J; Haynes BF; Montefiori DC; Tilton JC; Shaw GM; Hahn BH; Doms RW
J Virol; 2011 Sep; 85(17):8514-27. PubMed ID: 21715507
[TBL] [Abstract][Full Text] [Related]
14. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.
Cashin K; Jakobsen MR; Sterjovski J; Roche M; Ellett A; Flynn JK; Borm K; Gouillou M; Churchill MJ; Gorry PR
Retrovirology; 2013 Sep; 10():98. PubMed ID: 24041034
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
16. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.
Alexander M; Lynch R; Mulenga J; Allen S; Derdeyn CA; Hunter E
J Virol; 2010 Apr; 84(8):4100-4. PubMed ID: 20147398
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
Wang Q; Zhang S; Nguyen HT; Sodroski J
J Virol; 2024 Feb; 98(2):e0159423. PubMed ID: 38289101
[TBL] [Abstract][Full Text] [Related]
19. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
20. Implications of the 375W mutation for HIV-1 tropism and vaccine development.
Verdejo-Torres O; Vargas-Pavia T; Fatima S; Clapham PR; Duenas-Decamp MJ
J Virol; 2024 Jan; 98(1):e0152223. PubMed ID: 38169306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
